Company profile: Neuron Bio
1.1 - Company Overview
Company description
- Provider of innovative biosolutions: AlzTEST blood biomarker diagnostic for Alzheimer’s; Omega-3 DHA microalgae oil for functional foods and nutraceuticals; MicroBiOil platform for microbial oils and oleochemicals; Microbiotools by Neol for bioprocess development; custom R&D in biomedicine, toxicology and agro-food; and a drug discovery platform for neurodegenerative diseases.
Products and services
- AlzTEST®: Biomarker-based diagnostic test that analyzes blood biomarkers to help specialists diagnose patients at risk of developing Alzheimer’s disease
- Drug Discovery Platform: Neurodegeneration-focused platform that discovers and develops molecules aimed at preventing and treating neurodegenerative diseases, covering discovery research and development phases for therapeutic molecules
- MicroBiOil®: Renewable-resource-based platform that produces high-value oils and oleochemicals from microbial sources using renewable resources to generate bio-based oil products
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Neuron Bio
Knopp Biosciences
HQ: United States
Website
- Description: Provider of clinical-stage small-molecule treatments, including dexpramipexole for eosinophilic asthma and a Kv7 platform for epilepsy and other hyperexcitability disorders; engaged in drug discovery and development for neurological disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Knopp Biosciences company profile →
BlackThorn Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage neurobehavioral health, pioneering the next generation of artificial intelligence.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BlackThorn Therapeutics company profile →
NKGen Biotech
HQ: United States
Website
- Description: Provider of natural killer (NK) cell therapy candidates to restore immune function for cancer treatment, including SNK01, an autologous NK therapy in clinical trials for neurodegenerative diseases and various cancers, and SNK02, an allogeneic NK therapy being tested for solid tumors, plus an Expanded Access Program enabling access to investigational therapies under specific conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NKGen Biotech company profile →
Quoin Pharmaceuticals
HQ: United States
Website
- Description: Provider of pharmaceutical products under development addressing major unmet medical needs, including QRX003, a topical lotion in clinical evaluation for Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma; QRX008 for Scleroderma; QRX007 for Netherton Syndrome; and QRX004 for Epidermolysis Bullosa.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quoin Pharmaceuticals company profile →
iZumi Bio
HQ: United States
Website
- Description: Provider of biotechnology solutions leveraging cellular reprogramming, including induced pluripotent stem cells and directed differentiation, to develop stem cell-based therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full iZumi Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Neuron Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Neuron Bio
2.2 - Growth funds investing in similar companies to Neuron Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Neuron Bio
4.2 - Public trading comparable groups for Neuron Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →